The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
What are the most promising CAR T therapies in development for multiple myeloma?
The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Nina D. Shah, University of California, San Francisco, US, answers the question: What are the most promising CAR T therapies in development for multiple myeloma?
Dr Shah comments on some of the exciting abstracts due to be presented at the ASH meeting including; data from a longer follow-up of the LEGEND-2 trial in China, and the US equivalent trial, CARTITUDE, as well as an update from the bb21217 trial. Dr Shah also highlights an abstract on the use of a gamma secretase inhibitor, in combination with anti-BCMA CAR T, in order to increase BCMA expression on the myeloma-cell surface to improve efficacy.
Additionally, Dr Shah adds that there are more CAR T trials than ever before, with other strategies to improve efficacy including the targeting of multiple antigens. Lastly, Dr Shah notes that whilst it is not a CAR T product, some of the new bispecific T-cell engagers (BiTEs) are not given as a continuous infusion and therefore may represent another patient-friendly immunotherapy option.
What are the most promising CAR T therapies in development for multiple myeloma?